Home>Topics>Stocks>C.R. Bard

C.R. Bard

  1. All
  2. Commentary
  3. Stock Reports
  4. Fund Reports
  5. Headlines
  1. New Morningstar Analyst Report for C.R . Bard , Inc.

    Stock Reports

    Tue, 15 Apr 2014

    substantial market share decline for Bard. C . R . Bard 's line of infection-control products ..... when capital spending is low. We rate C . R . Bard 's stewardship as Standard. Chairman ..... lower executive compensation rates than C . R . Bard . We also would like to see more disclosure

  2. AngioDynamics Delivering The Growth, Margins Next?


    Fri, 11 Apr 2014

    past year. There are certainly considerable challenges left for AngioDynamics management, including taking share from Bard ( BCR ) and Teleflex ( TFX ) in vascular access and maximizing the value of newer offerings like BioFlo and AngioVac. Efforts to restructure

  3. ModernGraham Quarterly Valuation Of C.R . Bard Inc. - March 2014


    Tue, 1 Apr 2014

    By BCR data by YCharts Defensive Investor - must pass at least 6 of the following 7 tests: Score = 5/7 Adequate Size of Enterprise

  4. Update-Moody's changes outlook to stable on BCR's Ba2 ratings


    Tue, 1 Apr 2014

    For the full text of this story please click the following link:

  5. For Teleflex, Small Things Add Up


    Thu, 13 Mar 2014

    By Stephen Simpson, CFA : If companies like Intuitive Surgical and Heartware live on the "gee whiz" end of the med-tech spectrum, Teleflex ( TFX ) is on the other end. That is not to say that there isn't meaningful R&D and engineering going into the company's products, but categories like central

  6. CR Bard Underlying Business Remains Solid in Fourth Quarter


    Fri, 31 Jan 2014

    CR Bard released solid fourth-quarter performance that generally matched our expectations, and we are leaving our fair value estimate

  7. Our Outlook for Health-Care Stocks


    Tue, 31 Dec 2013

    see China as a strategic priority and invested heavily to put down roots there. On the other hand, Edwards EW and C . R . Bard BCR have invested far less extensively in China and do not seem to view penetration of this market as a corporate priority

  8. New Morningstar Analyst Report for Endo Health Solutions Inc

    Stock Reports

    Fri, 6 Dec 2013

    facing lawsuits related to patient injuries caused by its vaginal mesh products. The issue is not unique to Endo--competitors CR Bard , Boston Scientific, Johnson & Johnson, and others are facing litigation for similar products--but it could face a significant

  9. CR Bard Reports Strong 3Q and We Plan to Raise our Fair Value Estimate


    Tue, 22 Oct 2013

    CR Bard posted strong third-quarter results that slightly exceeded our expectations. We plan to modestly raise our fair value estimate

  10. New Endo CEO Off to Good Start, but Significant Challenges Remain


    Thu, 5 Sep 2013

    increased its litigation reserve to $216 million to account for the increase, but based on recent settlements of similar cases against competitors such as C . R . Bard , it wouldn't be surprising to see the final expense exceed that amount.

« Prev1234Next »
Content Partners